Product Pipeline
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
- Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
- Braftovi® (encorafinib) + Mektovi® (binimetinib): BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
- Duchenne Muscular Dystrophy Gene Therapy
- fidanacogene elaparvovec (Coagulation Factor IX Gene Therapy): Hemophilia
- giroctocogene fitelparvovec: Hemophilia Gene Therapy
- Ibrance® (palbociclib): High Risk Early Breast Cancer, Early Breast Cancer in Adjuvant Setting, HER2+ Breast Cancer
- Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
- Prophylactic Vaccine: Clostridioides difficile Infection
- Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata, Vitiligo
- Talzenna® (talazoparib): Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
- Xeljanz® (tofacitinib): Ankylosing Spondylitis
- Xtandi® (enzalutamide): Metastatic Hormone Sensitive Prostate Cancer, Non-Metastatic High Risk Hormone Sensitive Prostate Cancer
Pipeline Snapshot as of April 28, 2020
- Discovery Projects
- 27Phase 1
- 37Phase 2
- 21Phase 3
- 6Registration
- Total91
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK Inhibitor | 1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) | Phase 3 | Product Enhancement | Small Molecule |
PF-06801591 + Bacillus Calmette-Guerin (BCG) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Anti-PD-1 | Non-Muscle-Invasive Bladder Cancer (Biologic) | Phase 3 | New Molecular Entity | Biologic |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Product Enhancement | Small Molecule |
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor | Non-metastatic High Risk Hormone Sensitive Prostate Cancer | Phase 3 | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Merkel Cell Carcinoma (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/CMP-001 for Head and Neck Cancer | Phase 2 | Product Enhancement | Biologic |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | BRAF-mutant Metastatic Melanoma (ORPHAN - U.S.) | Phase 2 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | 1st Line BRAF-mutant Colorectal Cancer | Phase 2 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | 1st Line BRAF-mutant Non-Small Cell Lung Cancer | Phase 2 | Product Enhancement | Small Molecule |
Daurismo (glasdegib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: SMO (smoothened) antagonist | Myelodysplastic Syndrome | Phase 2 | Product Enhancement | Small Molecule |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | 2nd Line Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Product Enhancement | Small Molecule |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | Germline BRCA Mutated Locally Advanced Triple Negative Breast Cancer | Phase 2 | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/ Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic) | Phase 1 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Cancer (Biologic) | Phase 1 | Product Enhancement | Biologic |
PF-05082566 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: CD137 Agonist | Combo w/Kite Pharma'sYescarta (axicabtagene ciloleucel)forCancer | Phase 1 | New Molecular Entity | Biologic |
PF-06647020 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
